AzTrials
AzTrials

Diabetic FootNCT05551988

Predictors of Foot Amputation in Diabetic Foot Ulcers

An observational study of Diabetic Foot and Amputation, run by Bolan Medical Complex Hospital Quetta Pakistan at 1 site in Pakistan.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Diabetes affects 463 million population of the world. Diabetic foot is one of the complications of uncontrolled diabetes which can lead to amputation in 5- 24% of non-healing diabetic foot ulcers. Every 30 seconds a lower extremity is amputated in the world due to diabetes. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Retrospective observational study of diabetic foot ulcer
How many people
110 participants
Where
1 sitePakistan
Study dates
1 Jun 2021to 30 Jun 2022
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: All adult diabetic foot ulcer patients visiting endocrine department of tertiary care hospitals of Balochsitan, Pakistan with or with out amputation.

Who may be able to join

  • All diabetic foot patients (male and female) aged 18 and above;
  • Patients visiting Endocrine department of tertiary care hospitals of Balochistan, Pakistan

Who cannot join

  • Patients who have received prior treatment with antibiotics in the last one month
  • Patient with end stage renal disease requiring regular hemodialysis
  • Those with a history of previous vascular surgery of involved limb
  • Those who received hyperbaric oxygen therapy
  • Those with unrelated skin disease around the involved foot will be excluded.

Trial locations and contacts

1 site in 1 country.

Pakistan1 site
  • Bolan Medical Complex Hospital Quetta, Pakistan

    Quetta, Balochistan, 87300

Other trials in Pakistan

About this study

Official title: Predictors of Foot Amputation in Diabetic Foot Ulcers; A Retrospective Study From Pakistan

Diabetes affects 463 million population of the world. Diabetic foot is one of the complications of uncontrolled diabetes which can lead to amputation in 5- 24% of non-healing diabetic foot ulcers. Every 30 seconds a lower extremity is amputated in the world due to diabetes.

This is a retrospective study conducted in Balochistan, Pakistan. In this study investigators explored the risk factor of amputation in diabetic patients. Baseline characteristics, clinical profile, and lab tests were retrieved retrospectively and presented in the forms of tables. Investigators compared the categorical variables in amputees vs non-amputees and analyzed associated risk factors of amputation.

Read the detailed description

Proposal

In 2019 around 463 million (9.3%) of the global adult population (20-79 years) were estimated to be living with diabetes. This is a 62% increase from 2009 prevalence data which is projected to increase by another 10.9% (700 million) by 2045. What is surprising and more concerning is that almost half of the affected do not know they have diabetes. Pakistan with 19.6 million diabetics ranks fourth in terms of prevalence.

Uncontrolled diabetes leads to grave complications like diabetic retinopathy, neuropathy, nephropathy, and cardiovascular complications. Diabetic foot is one of the complications that causes significant disability. The global diabetic foot ulcer prevalence was 6.3% - 5.5% in Asia and with 13% in north America (13%). Although, majority (60-80%) of foot ulcers will heal, 5-24% of the remaining active ulcers will in the long run cause limb amputation within 6 to 18 months after the first evaluation. In fact, every 30 seconds in the world, a lower limb is amputated due to diabetes.

Diabetic foot amputations are associated with several risk factors, including peripheral vascular disease (PVD), neuropathy, longer diabetes duration, nephropathy, older age, poor glycemic control, comorbidities like coronary artery disease (CAD), preventive foot care, socioeconomic status, male gender, smoking, hypertension, and hyperlipidemia. Diabetic wound care management and foot care awareness and habits also play a definitive role in the outcome.

In this study investigators explored the baseline demographic, clinical, and lab investigations profile of diabetic foot patients visiting tertiary care hospitals of Baluchistan, Pakistan. Investigators also explored the associated risk factors of amputations in patients. The regional epidemiological knowledge and identifying the risk factors will guide physicians to improve patients' quality of life and reduce the economic burden for both the patient and the health care system.

Rationale of the study:

Antimicrobial surveillance studies of diabetic foot are the need of time to detect any variations in regional microbiological profile and rise in antimicrobial resistance, before it turns into a major public health nightmare. Addressing the risk factors of amputation in diabetic foot ulcer patients can avoid this dreadful complication. In this study investigators have attempted to address this void in regional data of diabetic foot. The results of this study will also guide physicians regarding appropriate choice of antibiotics, discourage indiscriminate abuse of antibiotics both by physicians and public, encourage practice of culture studies based treatment.

Operational definitions:

Diabetes Mellitus: Diagnosed at an HbA1C of greater than or equal to 6.5%; or a fasting blood glucose of more 126 mg/dl or higher Diabetic foot: Defined as a foot affected by ulceration that is associated with neuropathy and/or peripheral arterial disease of the lower limb in a patient with diabetes.

Hypertension: Previous medication of anti-hypertensive drug or a BP ≥ 140/90 mmHg).

Antibiotic resistance happens when germs like bacteria and fungi develop the ability to defeat the drugs designed to kill them. That means the germs are not killed and continue to grow.

Antibiotic resistance: When germs like bacteria and fungi develop the ability to defeat the drugs designed to kill them. That means the germs are not killed and continue to grow.

Multidrug resistance (MDR): Defined as acquired non-susceptibility to at least one agent in three or more antimicrobial categories, Extremely drug resistance (XDR): Defined as non-susceptibility to at least one agent in all but two or fewer antimicrobial categories (i.e. bacterial isolates remain susceptible to only one or two categories) Pan Drug resistance (PDR): Defined as non-susceptibility to all agents in all antimicrobial categories.

Duration and size of ulcer: Calculated by multiplying longest and widest diameters and expressed in centimeter square. Ulcers were graded using Wagner classification system, grade I (superficial ulcer or ulcer of subcutaneous tissue), grade II (ulcers extended into tendon, bone, or capsule), grade III (deep ulcer with osteomyelitis, or abscess), and grade IV (gangrene of toes). Subjects with grade 0 (uninfected lesions/ intact skin/ healed ulcers) were debarred from the study.

Amputation: Defined as the complete loss in the transverse anatomical plane of any part of the lower limb.

Diagnosis of infection involving bone: Done by either using a sterile probe in exposed bone or evidence obtained from plain radiographs.

Data collection procedure: Baseline characteristics of patients such as age, gender, residence district, rural or urban, education, income, HbA1c level, presence or absence of; neuropathy, peripheral arterial disease, amputation, grade and location of ulcer, and comorbidities will be retrieved from records and patient files. Incase of missing data patients shall be contacted for any previous records as needed.

Statistical analysis:

Quantitative variables represented as means ± standard deviation and categorical data as a percentage (%). SPSS and Microsoft Excel will be used to analyze the data . Chi square will be used to analyze for any difference between amputees and non amputees. Univariate logistic regression analysis will be applied to determine the odds ratio of variables as risk factors in amputees vs non amputees. Significant variable in univariate analysis will be entered in to multivariate logistic regression analysis.

Being tested
Retrospective observational study of diabetic foot ulcer
Keywords
antimicrobial resistance, antibiotic resistance, risk factors of amputation, predictors of amputation
Medical subject headings
Diabetic Foot

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Retrospective observational study of diabetic foot ulcerOther

    This is a retrospective observational study of antibiotic resistance and risk factors of amputation in diabetic foot ulcer patients

Study groups in NCT05551988
Study groupRoleWhat they receive
diabetic foot ulcer patientsDiabetic foot ulcer patients with and without diabetic foot amputation
Receives: Other: Retrospective observational study of diabetic foot ulcer

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Baseline characteristics of amputees vs non amputees

    Explore the baseline demographic, clinical, and lab investigations profile of diabetic foot patients visiting tertiary care hospitals of Baluchistan, Pakistan

    Measured: 10 months

  2. Predictors of amputation in diabetic foot ulcer patient

    Analyze the risk factors of amputation in diabetic foot ulcer patient

    Measured: 10 months

Secondary outcomes (1)
  1. Antibiotic resistance level

    Explore the resistance level to most common antibiotics in diabetic foot ulcer patients

    Measured: 10 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 Sep 2022
  2. Study start1 Jun 2021
  3. Primary completion30 Mar 2022
  4. Study completion30 Jun 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Retrospective
Enrolment
110 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05551988
Sponsor's protocol ID
BUMHS/IRB/22
Status last verified
Oct 2022
First submitted
20 Sep 2022
Last updated
25 Oct 2022
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided: Investigators will decide in future on how and when to share the IPD.

Publications

  • Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, Colagiuri S, Guariguata L, Motala AA, Ogurtsova K, Shaw JE, Bright D, Williams R; IDF Diabetes Atlas Committee. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019 Nov;157:107843. doi: 10.1016/j.diabres.2019.107843. Epub 2019 Sep 10.

    PubMed 31518657
  • Zhang P, Lu J, Jing Y, Tang S, Zhu D, Bi Y. Global epidemiology of diabetic foot ulceration: a systematic review and meta-analysis dagger. Ann Med. 2017 Mar;49(2):106-116. doi: 10.1080/07853890.2016.1231932. Epub 2016 Nov 3.

    PubMed 27585063
  • Alexiadou K, Doupis J. Management of diabetic foot ulcers. Diabetes Ther. 2012 Nov;3(1):4. doi: 10.1007/s13300-012-0004-9. Epub 2012 Apr 20.

    PubMed 22529027
  • Boulton AJ, Vileikyte L, Ragnarson-Tennvall G, Apelqvist J. The global burden of diabetic foot disease. Lancet. 2005 Nov 12;366(9498):1719-24. doi: 10.1016/S0140-6736(05)67698-2.

    PubMed 16291066
  • McEwen LN, Ylitalo KR, Herman WH, Wrobel JS. Prevalence and risk factors for diabetes-related foot complications in Translating Research Into Action for Diabetes (TRIAD). J Diabetes Complications. 2013 Nov-Dec;27(6):588-92. doi: 10.1016/j.jdiacomp.2013.08.003. Epub 2013 Sep 10.

    PubMed 24035357
  • Gershater MA, Londahl M, Nyberg P, Larsson J, Thorne J, Eneroth M, Apelqvist J. Complexity of factors related to outcome of neuropathic and neuroischaemic/ischaemic diabetic foot ulcers: a cohort study. Diabetologia. 2009 Mar;52(3):398-407. doi: 10.1007/s00125-008-1226-2. Epub 2008 Nov 27.

    PubMed 19037626
  • Yazdanpanah L, Shahbazian H, Nazari I, Arti HR, Ahmadi F, Mohammadianinejad SE, Cheraghian B, Hesam S. Incidence and Risk Factors of Diabetic Foot Ulcer: A Population-Based Diabetic Foot Cohort (ADFC Study)-Two-Year Follow-Up Study. Int J Endocrinol. 2018 Mar 15;2018:7631659. doi: 10.1155/2018/7631659. eCollection 2018.

    PubMed 29736169
  • Al-Rubeaan K, Al Derwish M, Ouizi S, Youssef AM, Subhani SN, Ibrahim HM, Alamri BN. Diabetic foot complications and their risk factors from a large retrospective cohort study. PLoS One. 2015 May 6;10(5):e0124446. doi: 10.1371/journal.pone.0124446. eCollection 2015.

    PubMed 25946144

Questions about this trial

What is this clinical trial studying?

An observational study of Diabetic Foot and Amputation, run by Bolan Medical Complex Hospital Quetta Pakistan at 1 site in Pakistan.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 25 Oct 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Baseline characteristics of amputees vs non amputees (time frame: 10 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05551988, which also lists 8 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Oct 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in